共 50 条
- [1] IPILIMUMAB 10 MG/KG INDUCTION DOSING PROMOTES T-CELL ACTIVATION IN PATIENTS WITH ADVANCED MELANOMAANNALS OF ONCOLOGY, 2008, 19 : 244 - 244Hoos, A.Chasalow, S. D.Parker, S. M.Siegel, J.Tsuchihashi, Z.Wu, D.Bennett, K.Alaparthy, S.Ronczka, A.Berman, D.
- [2] Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programmeCancer Immunology, Immunotherapy, 2013, 62 : 1021 - 1028Anna Maria Di GiacomoLuana CalabròRiccardo DanielliEster FonsattiErica BertocciIsabella PesceCarolina FazioOrnella CutaiaDiana GiannarelliClelia MiraccoMaurizio BiagioliMaresa AltomonteMichele Maio
- [3] Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programmeCANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (06) : 1021 - 1028Di Giacomo, Anna MariaCalabro, LuanaDanielli, RiccardoFonsatti, EsterBertocci, EricaPesce, IsabellaFazio, CarolinaCutaia, OrnellaGiannarelli, DianaMiracco, CleliaBiagioli, MaurizioAltomonte, MaresaMaio, Michele
- [4] Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trialsEJC SUPPLEMENTS, 2009, 7 (02): : 578 - 578Maio, M.Lebbe, C.Sileni, V. ChiarionSiegel, J.Hoos, A.Humphrey, R.O'Day, S.Wolchok, J.Weber, J.Harmankaya, K.
- [5] Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trialsJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Lebbe, CelesteWeber, Jeffrey S.Maio, MicheleNeyns, BartHarmankaya, KaanHamid, OmidO'Day, StevenChin, Kevin M.McDowell, Diane OpattCykowski, LoriMcHenry, BrentWolchok, Jedd D.
- [6] LONG-TERM SURVIVAL OF PATIENTS WITH ADVANCED MELANOMA TREATED SECOND LINE WITH IPILIMUMABANNALS OF ONCOLOGY, 2012, 23 : 370 - 370Lee, D.Pericleous, L.Lebmeier, M.Winn, B.Batty, A.Nikoglou, T.
- [7] Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaJOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17Ascierto, Paolo A.Del Vecchio, MicheleMackiewicz, AndrzejRobert, CarolineChiarion-Sileni, VannaArance, AnaLebbe, CelesteSvane, Inge MarieMcNeil, CatrionaRutkowski, PiotrLoquai, CarmenMortier, LaurentHamid, OmidBastholt, LarsDreno, BrigitteSchadendorf, DirkGarbe, ClausNyakas, MartaGrob, Jean-JacquesThomas, LucLiszkay, GabriellaSmylie, MichaelBurcin, SimsekHosein, FareedaMaio, Michele
- [8] Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)Ascierto, Paolo AntonioDel Vecchio, MicheleMackiewicz, AndrzejRobert, CarolineChiarion-Sileni, VannaArance, AnaLebbe, CelesteSvane, Inge MarieMcNeil, CatrionaRutkowski, PiotrLoquai, CarmenMortier, LaurentHamid, OmidBastholt, LarsDreno, BrigitteSchadendorf, DirkGarbe, ClausNyakas, MartaGrob, Jean-JacquesThomas, LucLiszkay, GabriellaSmylie, MichaelHoeller, ChristophFerraresi, VirginiaGrange, FlorentGutzmer, RalfPikiel, JoannaHosein, FareedaSimsek, BurcinMaio, Michele
- [9] Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazineJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Hersh, E.Weber, J.Powderly, J.Pavlik, A.Nichol, G.Yellin, M.Cranmer, L.Urba, W.O'Day, S.
- [10] Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trialsJournal of Translational Medicine, 12 (Suppl 1)Reinhard DummerDirk SchadendorfPaolo A AsciertoJames LarkinCeleste LebbéAxel Hauschild